Positive News SentimentPositive NewsNASDAQ:FEMY Femasys (FEMY) Stock Price, News & Analysis $0.37 -0.01 (-2.00%) As of 01:07 PM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Femasys Stock (NASDAQ:FEMY) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Femasys alerts:Sign Up Key Stats Today's Range$0.37▼$0.3950-Day Range$0.34▼$0.6052-Week Range$0.31▼$1.11Volume681,387 shsAverage Volume923,043 shsMarket Capitalization$22.47 millionP/E RatioN/ADividend YieldN/APrice Target$5.33Consensus RatingModerate Buy Company Overview Femasys International, Inc. is a medical device company focused on the research, development and commercialization of innovative technologies for interventional women’s health applications. The company’s core activities center on creating minimally invasive diagnostic and therapeutic products designed to address uterine cavity evaluation and treatment and to improve outcomes in gynecological care. The company’s flagship product, the FemVue® hydrosonography system, is a single-use catheter-based device that enhances visualization of the uterine cavity through saline infusion sonography. This system is intended to facilitate earlier and more accurate diagnosis of intrauterine abnormalities such as polyps, fibroids and adhesions. Femasys is also developing a pipeline of complementary devices aimed at expanding its portfolio of interventional gynecological tools. Femasys is listed on the Nasdaq under the ticker symbol FEMY and is incorporated in Delaware with principal executive offices in Beijing, China. The company’s leadership team includes medical device veterans with deep experience in product development, regulatory affairs and commercial strategy. Femasys continues to pursue regulatory clearances in key markets, including CE marking in Europe, while exploring opportunities to introduce its technologies across Asia, North America and other regions.AI Generated. May Contain Errors. Read More Femasys Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks53rd Percentile Overall ScoreFEMY MarketRank™: Femasys scored higher than 53% of companies evaluated by MarketBeat, and ranked 531st out of 871 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.7 / 5Analyst RatingModerate Buy Consensus RatingFemasys has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on no strong buy ratings, 3 buy ratings, no hold ratings, and 1 sell rating.Upside PotentialFemasys has a consensus price target of $5.33, representing about 1,333.7% upside from its current price of $0.37.Amount of Analyst CoverageFemasys has only been the subject of 2 research reports in the past 90 days.Read more about Femasys' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Femasys is -1.38, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Femasys is -1.38, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioFemasys has a P/B Ratio of 3.10. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Femasys' valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted3.50% of the float of Femasys has been sold short.Short Interest Ratio / Days to CoverFemasys has a short interest ratio ("days to cover") of 4.28.Change versus previous monthShort interest in Femasys has recently increased by 1.20%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldFemasys does not currently pay a dividend.Dividend GrowthFemasys does not have a long track record of dividend growth. News and Social Media4.3 / 5News SentimentN/A News SentimentFemasys has a news sentiment score of 1.87. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.80 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Femasys this week, compared to 2 articles on an average week.Search Interest9 people have searched for FEMY on MarketBeat in the last 30 days. This is an increase of 350% compared to the previous 30 days.MarketBeat Follows5 people have added Femasys to their MarketBeat watchlist in the last 30 days. This is an increase of 400% compared to the previous 30 days. Company Ownership1.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Femasys insiders have not sold or bought any company stock.Percentage Held by Insiders7.55% of the stock of Femasys is held by insiders.Percentage Held by Institutions65.27% of the stock of Femasys is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Femasys' insider trading history. Receive FEMY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Femasys and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. FEMY Stock News HeadlinesFemasys (FEMY) Stock Forecast & Price TargetMay 19, 2026 | investing.comFemasys Amends Financing Terms and Issues New WarrantsMay 19, 2026 | theglobeandmail.comThe Iran War Just Broke the Gold MarketThe Iran war isn't just a geopolitical event. It's a financial one. Within hours of the strikes, oil surged… Defense stocks exploded…And gold ripped past $5,000.May 29 at 1:00 AM | Behind the Markets (Ad)Femasys updates corporate presentation on women’s health portfolioMay 13, 2026 | tipranks.comFemasys Expands Fertility Care Portfolio in Europe with CE Mark Approval for FemHSG™ CatheterMay 13, 2026 | globenewswire.comFemasys Inc.: Femasys Announces Financial Results for Quarter Ended March 31, 2026 and Provides Corporate UpdateMay 9, 2026 | finanznachrichten.deFemasys Announces Financial Results for Quarter Ended March 31, 2026 and Provides Corporate UpdateMay 8, 2026 | globenewswire.comFemasys Enables OB/GYNs to Deliver First-Line Fertility Treatment with Initial Commercial Use of FemaSeed® CompleteMay 5, 2026 | globenewswire.comSee More Headlines FEMY Stock Analysis - Frequently Asked Questions How have FEMY shares performed this year? Femasys' stock was trading at $0.5762 at the start of the year. Since then, FEMY shares have decreased by 35.4% and is now trading at $0.3720. How were Femasys' earnings last quarter? Femasys Inc. (NASDAQ:FEMY) announced its quarterly earnings results on Friday, May, 8th. The company reported $0.00 EPS for the quarter, topping the consensus estimate of ($0.07) by $0.07. The company had revenue of $0.42 million for the quarter, compared to analyst estimates of $0.77 million. Femasys had a negative net margin of 521.97% and a negative trailing twelve-month return on equity of 258.08%. When did Femasys IPO? Femasys (FEMY) raised $34 million in an initial public offering (IPO) on Wednesday, June 16th 2021. The company issued 2,650,000 shares at a price of $12.00-$14.00 per share. Chardan and JonesTrading served as the underwriters for the IPO. How do I buy shares of Femasys? Shares of FEMY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Femasys own? Based on aggregate information from My MarketBeat watchlists, some other companies that Femasys investors own include Sangamo Therapeutics (SGMO), Aurora Cannabis (ACB), Canoo (GOEV), FuelCell Energy (FCEL), Agenus (AGEN), Geron (GERN) and Eos Energy Enterprises (EOSE). Company Calendar Last Earnings5/08/2026Today5/29/2026Next Earnings (Estimated)8/12/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (2m+) 1-Year History May 25 Aug 25 Nov 25 Feb 26 May 26 FEMY's financial health is in the Yellow zone, according to TradeSmith. FEMY has been in this zone for over 2 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryMedical Equipment Current SymbolNASDAQ:FEMY CIK1339005 Webwww.femasys.com Phone770-500-3910FaxN/AEmployees30Year Founded2004Price Target and Rating Average Price Target for Femasys$5.33 High Price Target$8.00 Low Price Target$1.50 Potential Upside/Downside+1,333.7%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage4 Analysts Profitability EPS (Trailing Twelve Months)($0.27) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$18.63 million Net Margins-521.97% Pretax Margin-500.00% Return on Equity-258.08% Return on Assets-73.72% Debt Debt-to-Equity Ratio0.53 Current Ratio3.91 Quick Ratio1.98 Sales & Book Value Annual Sales$2.29 million Price / Sales9.81 Cash FlowN/A Price / Cash FlowN/A Book Value$0.12 per share Price / Book3.10Miscellaneous Outstanding Shares60,390,000Free Float55,831,000Market Cap$22.47 million OptionableNot Optionable Beta-2.26 Social Links The 10 Best High-Yield Dividend Stocks for 2026Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free Report This page (NASDAQ:FEMY) was last updated on 5/29/2026 by MarketBeat.com Staff. From Our PartnersThe 1934 playbookIn 1934, a legal government maneuver transferred billions in wealth overnight. Most Americans never saw it com...American Alternative | SponsoredSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...Brownstone Research | Sponsored$30 stock to buy before Starlink goes public (WATCH NOW!)In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...Paradigm Press | SponsoredTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredMy feud with Zohran MamdaniEmmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...Stansberry Research | SponsoredSpaceX just filed. The clock is ticking.Reuters reports Elon Musk filed secretly. Barron's says it's being finalized behind closed doors. CNBC just re...The Oxford Club | SponsoredSpaceX will mint billionaires. You won't be one of them.By the time a company goes public, 95% of profits have already been made. Insiders bought SpaceX at $20 billio...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Femasys Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Femasys With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
